You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.
The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The institute will use Curetis' Unyvero Hospitalized Pneumonia panel on high-risk patients admitted to the ICU for COVID-19 pneumonia.
The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.
Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.
The Warsaw, Poland-based firm will also use some of the funding to commercialize a phenotypic antibiotic susceptibility testing system.
Inspirata said that the partners will combine their digital pathology products to address challenges with traditional pathology testing for H. Pylori.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.